3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase 1
2
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
6
Lymphoma
3
Lymphoma, T-Cell, Cutaneous
2
Hematologic Diseases
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Primary Cutaneous Anaplastic Large Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Dendritic Cell Sarcoma, Interdigitating
1
Interventions
Rituximab
66
Cyclophosphamide
46
Vincristine
40
Doxorubicin
40
Prednisone
35
Etoposide
19
Radiotherapy
14
Gemcitabine
13
Peripheral Blood Stem Cell Transplantation
12
Filgrastim
12
Cytarabine
12
Lenalidomide
11
Carmustine
10
VAP-cyclo protocol
9
Prednisolone
9
Oxaliplatin
9
Melphalan
9
Methotrexate
7
Ifosfamide
7
Mitoxantrone
6
Bleomycin
6
polatuzumab vedotin
5
R-CHOP protocol
4
Methylprednisolone
4
Injections
4
Granulocyte Colony-Stimulating Factor
4
Cyclosporine
4
Cisplatin
4
Carboplatin
4
pegfilgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Large B-Cell, Diffuse
×
Brentuximab Vedotin
×
Clear all
NCT04404283
2026-04-20
ECHELON-3
Seagen Inc.
Phase 3
Active not recruiting
239 enrolled
1 FDA